Tianjin Medical University Cancer Institute & Hospital
Welcome,         Profile    Billing    Logout  
 56 Trials 
81 Trials

   Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Townsend, Amanda
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
Lu, Shun
RATIONALE-304, NCT03663205: A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous Non-small Cell Lung Cancer

Checkmark Submitted for adv/met 2L NSCLC; in combination with carboplatin & either paclitaxel/ nab-paclitaxel for adv/met 1L sqNSCLC and; pemetrexed & platinum-containing chemotherapy for adv/met 1L non-sq NSCLC
Apr 2022 - Apr 2022: Submitted for adv/met 2L NSCLC; in combination with carboplatin & either paclitaxel/ nab-paclitaxel for adv/met 1L sqNSCLC and; pemetrexed & platinum-containing chemotherapy for adv/met 1L non-sq NSCLC
Checkmark Approved in China for 1L treatment of advanced NSCLC
Jun 2021 - Jun 2021: Approved in China for 1L treatment of advanced NSCLC
Checkmark From trial in combination with chemotherapy for 1L NSCLC at ESMO 2020
More
Completed
3
334
RoW
Tislelizumab, Tevimbra, BGB-A317, Cisplatin, Carboplatin, Pemetrexed
BeiGene
Non-Small Cell Lung Cancer
01/20
04/23
FGCL-4592-898, NCT05301517: A Study to Evaluate the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Participants Receiving Chemotherapy Treatment for Non-Myeloid Malignancies

Completed
3
159
RoW
SEPO®, Recombinant human erythropoietin-α [rHuEPO-α], Roxadustat, FG-4592
FibroGen
Chemotherapy Induced Anemia
04/23
04/23
ORIENT-31, NCT03802240: Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure

Hourglass Jan 2022 - Dec 2022 : Approval for 2L NSCLC
Checkmark Interim analysis results of P3 ORIENT-31 study in EGFR-mutated non-squamous NSCLC at ESMO 2022
Sep 2022 - Sep 2022: Interim analysis results of P3 ORIENT-31 study in EGFR-mutated non-squamous NSCLC at ESMO 2022
Checkmark Accepted sNDA in China for EGFR-mutated non-squamous NSCLC who progressed after EGFR-TKI therapy
Dec 2021 - Dec 2021: Accepted sNDA in China for EGFR-mutated non-squamous NSCLC who progressed after EGFR-TKI therapy
More
Completed
3
492
RoW
Sintilimab, IBI308, IBI305, Pemetrexed, Cisplatin, Placebo1, Placebo2
Innovent Biologics (Suzhou) Co. Ltd.
Non-Squamous Non-Small Cell Lung Cancer
07/21
06/23
ZKAB001-LEES-2020-07, NCT04878016: A Study of Carboplatin Plus Etoposide With or Without ZKAB001 (Anti-PD-L1 Antibody) in Patients With ES-SCLC

Completed
3
498
RoW
ZKAB001, Placebo, Carboplatin, Etoposide
Lee's Pharmaceutical Limited
Extensive-stage Small-cell Lung Cancer
10/23
10/23
LAURA, NCT03521154 / 2018-001061-16: A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer

Hourglass Jan 2022 - Dec 2023 : From LAURA trial for unresectable EGFRm stage III NSCLC
Hourglass Jan 2022 - Dec 2023 : Acceptance of regulatory submission in US (based on LAURA trial) for unresectable NSCLC
Active, not recruiting
3
216
Europe, Japan, US, RoW
Osimertinib 80mg/40mg, Placebo Osimertinib 80mg/40mg
AstraZeneca
Non Small Cell Lung Cancer (Stage III)
01/24
06/26
AENEAS2, NCT04923906: Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR Mutations

Active, not recruiting
3
624
RoW
Aumolertinib, HS-10296, Placebo Aumolertinib
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Non-small Cell Lung Cancer
06/24
01/26
NCT06300177: D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure

Recruiting
3
522
RoW
D-1553 Tablet, Docetaxel injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Non Small Cell Lung Cancer
10/26
12/27
NCT04923945: Savolitinib for Treating Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Patients

Recruiting
3
163
RoW
Savolitinib
Hutchison Medipharma Limited
Non-small Cell Lung Cancer Metastatic
07/24
12/24
SHR-A1811-310, NCT06430437: A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations

Not yet recruiting
3
300
RoW
SHR-A1811, Camrelizumab、Pemetrexed/ Paclitaxel、Carboplatin/ Cisplatin
Jiangsu HengRui Medicine Co., Ltd.
Non-Small Cell Lung Cancer With HER2- Mutations
02/26
04/27
SACHI, NCT05015608: Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification

Recruiting
3
250
RoW
Savolitinib + Osimertinib, Pemetrexed + Cisplatin /Carboplatin
Hutchison Medipharma Limited
Non-small Cell Lung Cancer
09/24
11/24
AK112-306, NCT05840016: AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer

Recruiting
3
396
RoW
AK112, Carboplatin, Paxlitaxel, Tislelizumab, Carboplatin, Paxlitaxel
Akeso
Advanced Squamous Non Small Cell Lung Cancer
12/24
12/25
AdvanTIG-302, NCT04746924 / 2020-004985-21: A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

Active, not recruiting
3
662
Europe, Japan, US, RoW
Tislelizumab, BGB-A317, Ociperlimab, BGB-A1217, Pembrolizumab, KEYTRUDA, Placebo
BeiGene
Non-small Cell Lung Cancer, NSCLC
10/26
02/27
SAFFRON, NCT05261399 / 2021-006374-24: Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment

Recruiting
3
324
Europe, Canada, Japan, US, RoW
Savolitinib, AZD6094, HMPL-504, volitinib, Osimertinib, AZD9291, Tagrisso, Pemetrexed, NAP, Cisplatin, Carboplatin
AstraZeneca, AstraZeneca AB
Carcinoma, Non-Small-Cell Lung
06/25
12/26
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Recruiting
3
1016
Europe, Canada, Japan, US, RoW
LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed
Eli Lilly and Company, Loxo Oncology, Inc.
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
10/26
10/29
NCT06041776: Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations

Recruiting
3
570
RoW
Befotertinib + Icotinib placebo, Icotinib + Befotertinib placebo
Betta Pharmaceuticals Co., Ltd.
Non-Small Cell Lung Cancer, EGFR Sensitive Mutation, Adjuvant Therapy
04/28
11/29
NCT04206072: D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLC

Active, not recruiting
2/3
362
RoW
D-0316 Capsule, Icotinib Hydrochloride Tablets, Conmana
Betta Pharmaceuticals Co., Ltd.
Non-Small Cell Lung Cancer, EGFR Gene Mutation
07/22
12/24
NCT04412564: A Study of TQ-B3101 Capsules in Subjects With Advanced Malignant Tumor

Recruiting
2
200
RoW
TQ-B3101
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Malignant Tumor
03/21
09/21
NCT03861156: D-0316 in Patients With EGFR Positive Non Small Cell Lung Cancer

Completed
2
290
RoW
D-0316
InventisBio Co., Ltd
Solid Tumor, NSCLC, EGFR T790M
08/21
05/23
NCT02897479: A Phase II Study of HMPL-504 in Lung Sarcomatoid Carcinoma and Other Non-small Cell Lung Cancer

Active, not recruiting
2
76
RoW
Savolitinib, hmpl-504
Hutchison Medipharma Limited
Lung Sarcomatoid Carcinoma
12/21
12/21
NCT05078931: A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients

Recruiting
2
35
RoW
Pembrolizumab, Keytruda, Lenvatinib, Lenvima
Shanghai Chest Hospital, Merck Sharp & Dohme Corp.
NSCLC
10/22
05/24
NCT04290325: HMPL-453 in Advanced Malignant Mesothelioma

Recruiting
2
27
RoW
HMPL-453
Hutchison Medipharma Limited
Advanced Malignant Mesothelioma
11/22
03/23
NCT06147570: A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

Recruiting
2
62
RoW
HS-10365 capsules
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Nonsmall Cell Lung Cancer
08/27
08/28
MRG002-008, NCT05141786: A Study of MRG002 in the Treatment of Patients With HER2-mutated Unresectable/Metastatic Non-small Cell Lung Cancer (NSCLC).

Not yet recruiting
2
100
RoW
MRG002
Shanghai Miracogen Inc.
Non-small- Cell Lung Cancer (NSCLC)
12/23
12/23
NCT06737081: SAL-0951 in the Treatment of Chemotherapy-induced Anemia in Patients With Non-myeloid Malignancies

Recruiting
2
60
RoW
SAL-0951 tablets 4mg, SAL-0951 tablets 4mg group, SAL-0951 tablets 5mg, SAL-0951 tablets 5mg group
Shenzhen Salubris Pharmaceuticals Co., Ltd.
Anemia
12/25
06/26
SOUND, NCT05374603: Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC

Active, not recruiting
2
47
RoW
Savolitinib, Durvalumab
AstraZeneca
Lung Cancer
08/25
08/25
NCT06668103: A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib

Recruiting
2
54
RoW
ABSK043 in combination with Firmonertinib
Abbisko Therapeutics Co, Ltd
Non-Small Cell Lung Cancer With EGFR Mutation
12/27
06/28
HLX26HLX10-NSCLC201, NCT05787613: A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC Patients

Recruiting
2
132
RoW
HLX26, Anti-LAG-3 monoclonal Antibody Injection, Serplulimab, HLX10, Chemotherapy drug, Placebo
Shanghai Henlius Biotech
NSCLC Stage IV
07/25
07/27
NCT06373406: A Study of MHB036C for Advanced Solid Tumor

Recruiting
1/2
200
RoW
MHB036C
Minghui Pharmaceutical (Hangzhou) Ltd
Advanced Solid Tumor
08/24
12/24
GLORY, NCT04270591: Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer

Recruiting
1/2
183
Japan, US, RoW
Glumetinib, SCC244
Haihe Biopharma Co., Ltd.
C-Met Exon 14 Mutation
10/23
12/23
SHR-A1811-II-203, NCT05482568: A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer

Recruiting
1/2
324
RoW
SHR-A1811 & Pyrotinib/SHR-A1811 & SHR-1316
Jiangsu HengRui Medicine Co., Ltd.
Advanced Non-small Cell Lung Cancer
11/23
12/24
NCT05383898: Study to Evaluate D-1553 in Subjects With Lung Cancer

Completed
1/2
225
RoW
D-1553
InventisBio Co., Ltd
NSCLC
11/23
05/24
NCT05492045: A Study to Evaluate D-1553 in Combination Therapy in Non-Small Cell Lung Cancer

Terminated
1/2
22
RoW
D-1553, Other
InventisBio Co., Ltd
NSCLC
06/24
06/24
NCT05207787: Phase Ⅰ/Ⅱ Study of the HS-10365 in Patients With Advanced Solid Tumors

Recruiting
1/2
306
RoW
HS-10365
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Solid Tumor
04/24
12/25
NCT06500676: A Study of GFH375 in Patients with Advanced Solid Tumors with KRAS G12D Mutations

Recruiting
1/2
290
RoW
GFH375
Genfleet Therapeutics (Shanghai) Inc.
KRAS G12D Mutations, Advanced Solid Tumors
07/28
12/28
NCT06283719: Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer

Recruiting
1/2
105
RoW
ZG006
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Small Cell Lung Cancer, Neuroendocrine Cancer
04/26
04/26
NCT06754930: A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC

Not yet recruiting
1/2
400
RoW
SHR-1826, SHR-1316, SHR-9839, SHR-8068, Ametinib mesylate, BP-102, Carboplatin
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Non-small Cell Lung Cancer (NSCLC)
12/27
12/27
NCT05552781: H002 in Patients With EGFR Mutation Locally Advanced or Metastatic NSCLC

Recruiting
1/2
76
RoW
H002 capsule, H002
RedCloud Bio, R&G Pharma Studies Co.,Ltd.
Non-small Cell Lung Cancer
02/25
02/25
NCT05641493: A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of HLX208+HLX10 in NSCLC With BRAF V600E Mutation

Recruiting
1/2
49
RoW
HLX208+HLX10
Shanghai Henlius Biotech
Non Small Cell Lung Cancer
03/25
02/26
NCT05951608: A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors

Not yet recruiting
1/2
216
NA
AK127 in combination with AK112
Akeso
Advanced Solid Tumors
07/25
07/26
NCT05731518: SC0245 and Irinotecan in Treating Patients With Relapsed Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

Recruiting
1/2
67
RoW
SC0245, SC0245 tablet, Irinotecan, Irinotecan hydrochloride injection
Biocity Biopharmaceutics Co., Ltd.
Small Cell Lung Cancer
09/25
02/26
DB-1310-O-1001, NCT05785741: A Study of DB-1310 in Advanced/Metastatic Solid Tumors

Recruiting
1/2
1000
US, RoW
DB-1310, Trastuzumab, Osimertinib
DualityBio Inc.
Advanced Solid Tumor
08/26
08/26
TRIDENT-1, NCT03093116 / 2016-003616-13: A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Hourglass Jan 2025 - Jan 2025 : Approval in EU for adv ROS1+ve NSCLC, adv NTRK+ve solid tumors
Hourglass Jan 2023 - Dec 2023 : Data readout from P1/2 TRIDENT-1 trial for ROS1 NSCLC and NTRK+ solid tumors
Jan 2023 - Dec 2023: Approval in US for 2L NSCLC
Hourglass Jul 2023 - Dec 2023 : Approval for ROS1+ NSCLC
Checkmark Top line data across ROS1-positive TKI-naïve and TKI-pretreated NSCLC cohorts in TRIDENT-1 trial
More
Recruiting
1/2
500
Europe, Canada, Japan, US, RoW
Oral repotrectinib (TPX-0005), repotrectinib
Turning Point Therapeutics, Inc., Zai Lab (Shanghai) Co., Ltd.
Locally Advanced Solid Tumors, Metastatic Solid Tumors
02/28
02/28
NCT03976856: Safety and Efficacy of Genolimzumab (GB226) in Combination With Fruquintinib

Recruiting
1
42
RoW
GB226, Geptanolimab, Fruquintinib, HMPL-013
Genor Biopharma Co., Ltd., Hutchison Medipharma Limited
Metastatic Non-small Cell Lung Cancer
12/21
12/22
NCT04671849: An Open Label, Multi-center, Phase I Clinical Study to Evaluate the Safety, Effectiveness and Pharmacokinetic Characteristics of SIM1803-1A in Patients With Locally Advanced/Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene Fusion Mutations.

Recruiting
1
243
RoW
SIM1803-1A
Jiangsu Simcere Pharmaceutical Co., Ltd.
Advanced or Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene Fusion
09/22
01/24
NCT04346914: Study of ZKAB001 Combined With Carboplatin and Etoposide in the Extensive Small Cell Lung Cancer

Recruiting
1
20
RoW
recombinant anti-PD-L1 monoclonal antibody injection combined with carboplatin and etoposide
Lee's Pharmaceutical Limited
Extensive Stage Small Cell Lung Cancer
10/22
10/22
NCT04866485: A Study to Evaluate Safety, Tolerability, PK/PD and Preliminary Efficacy of HBM4003 Combined With Anti-PD-1 Antibody

Not yet recruiting
1
66
NA
HBM4003 and pembrolizumab, HBM4003
Harbour BioMed (Guangzhou) Co. Ltd.
Solid Tumor
02/23
02/23
NCT05055232: A Phase I Study of XZP-3621 in Chinese Patients With ALK or ROS1 Rearrangement Non-small Cell Lung Cancer

Recruiting
1
120
RoW
XZP-3621
Xuanzhu Biopharmaceutical Co., Ltd.
ROS1 Rearrangement Non-small Cell Lung Cancer, ALK Rearrangement Non-small Cell Lung Cancer
03/23
09/23
NCT05393063: A Study to Evaluate the Efficacy and Safety of AK127 in Patients With Advanced Solid Tumors

Not yet recruiting
1
36
NA
AK127, Subjects will receive AK127 by intravenous administration
Akeso
Advanced Solid Tumors
06/23
06/24
NCT05315180: A Phase 1,Open-label Study of BPI-421286 in Subjects With Advanced Solid Tumors

Recruiting
1
80
RoW
BPI-421286
Betta Pharmaceuticals Co., Ltd.
Malignant Neoplasms, Metastatic Cancer
07/23
07/23
NCT05223595: A Study of Gentuximab in Combination With Almonertinib in EGFR Mutation-positive Metastatic NSCLC

Recruiting
1
42
RoW
Gentuximab, Almonertinib
GeneScience Pharmaceuticals Co., Ltd.
Metastatic Non-Small Cell Lung Cancer
09/23
01/24
NCT04843033: A Study to Investigate Safety and Tolerability of SH3809 Tablet in Patients With Advanced Solid Tumors

Recruiting
1
55
RoW
SH3809 tablet
Nanjing Sanhome Pharmaceutical, Co., Ltd.
Advanced Solid Tumor
10/23
12/23
NCT05430386: Study of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLC

Recruiting
1
174
RoW
HS-10241, Almonertinib
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Non Small Cell Lung Cancer
12/23
12/23
NCT06225804: A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK112 in Patients With Non-Small Cell Lung Cancer

Recruiting
1
164
US, RoW
ABSK112, EGFR Exon20 inhibitor
Abbisko Therapeutics Co, Ltd
Non-Small Cell Lung Cancer
03/27
03/28
AK112-103, NCT05116007: Anti-PD-1 and VEGF Bispecific Antibody AK112 in Combination With Chemotherapy in Patients With ES-SCLC

Completed
1
35
RoW
AK112, Etoposide, Carboplatin
Akeso
SCLC, Extensive Stage
12/23
12/23
NCT05653869: A Study of APS03118 in Advanced Solid Tumors Harboring RET Mutations or Fusions

Recruiting
1
35
RoW
APS03118, APS03118 administrated orally
Applied Pharmaceutical Science, Inc.
RET-altered Solid Tumors
04/24
04/25
NCT06328439: A Study to Evaluate ANS014004 in Subjects With Locally Advanced or Metastatic Solid Tumors

Recruiting
1
264
RoW
ANS014004
Avistone Biotechnology Co., Ltd., Shanghai Chest Hospital, Hunan Cancer Hospital, Henan Cancer Hospital, Zhejiang Cancer Hospital, Peking University Cancer Hospital & Institute
Locally Advanced or Metastatic Solid Tumors
12/27
01/28
CIBI363A103, NCT06468098: A Study of IBI363 in Subjects With Advanced Malignancies

Recruiting
1
556
RoW
IBI363 + chemotherapy, IBI363 + Investigator's Choice SOC
Innovent Biologics (Suzhou) Co. Ltd.
Advanced Malignancies
06/25
12/26
MIZAR-005, NCT06473961: A Phase Ⅰb Study on Autologous GC101 TIL Injection for the Treatment of NSCLC

Recruiting
1
20
RoW
Autologous Tumor Infiltrating Lymphocytes, GC101 TIL injection
Shanghai Juncell Therapeutics
Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer
01/26
07/27
NCT05244551: A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors

Recruiting
1
85
US, RoW
ABSK061
Abbisko Therapeutics Co, Ltd
Solid Tumor
04/25
04/25
NCT05717348: A Study of ES014 in Patients With Locally Advanced or Metastatic Solid Tumours

Recruiting
1
120
RoW
ES014
Elpiscience (Suzhou) Biopharma, Ltd.
Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor
06/25
09/25
NCT05911464: A Phase I Study of HS-10386 in Participants With Advanced Solid Tumors

Recruiting
1
248
RoW
HS-10386
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Advanced Solid Tumor
10/25
10/27
NCT05914545: A Study of FZ-AD004 in Patients with Advanced Solid Tumors

Recruiting
1
121
RoW
FZ-AD004, FZ-AD004-Antibody-drug Conjugate
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Advanced and Metastatic Solid Tumor
12/25
12/25
NCT06015568: Study of MCLA-129 Combined With Befotertinib in the Treatment of Advanced Non-small Cell Lung Cancer With EGFR Sensitive Mutation

Not yet recruiting
1
172
RoW
MCLA-129: 1500mg or 2000mg IV Q2W, Befotertinib: 75 mg or 100 mg Po QD
Betta Pharmaceuticals Co., Ltd.
Non-Small Cell Lung Cancer、EGFR Sensitive Mutation
11/28
07/29
NCT04566432: Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated NSCLC Patients

Recruiting
N/A
250
RoW
Observation
Geneplus-Beijing Co. Ltd., Shanghai Chest Hospital
Lung Neoplasms, Lung Cancer, Nonsmall Cell, Adenocarcinoma of Lung, Squamous Cell Lung Cancer
12/24
06/25
NCT05965557: Exploration of Predictive Markers of Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer

Recruiting
N/A
100
RoW
Geneplus-Beijing Co. Ltd.
Lung Cancer
12/25
12/25
MEANING-20, NCT05863819: A Real World Study of Mobocertinib in Adults With Lung Cancer in China (MEANING)

Withdrawn
N/A
120
RoW
No Intervention
Takeda
Non-small Cell Lung Cancer (NSCLC)
12/26
02/27
Yao, Wenxiu
OFFER, NCT04536558: Olanzapine Plus Fosaprepitant Standard Antiemetic Therapy in the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients Receiving High Emetic Risk Multi-day Chemotherapy: a Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study

Not yet recruiting
3
352
RoW
olanzapine plus fosaprepitant-based triple regimen, placebo plus fosaprepitant-based triple regimen
Sun Yat-sen University, Jiangsu Hansoh Pharmaceutical Co., Ltd.
Solid Tumor Patients Receiving High Emetic Risk Multi-day Chemotherapy
02/21
03/21
PYRAMID-1, NCT04447118 / 2020-000951-11: Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy

Active, not recruiting
3
151
Europe, US, RoW
Pyrotinib, Irene, Docetaxel, Docetaxel injection
Jiangsu HengRui Medicine Co., Ltd.
Non-squamous NSCLC, HER2 Exon 20 Mutation
06/23
10/23
NCT05042375: A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer

Recruiting
3
450
RoW
camrelizumab + famitinib, pembrolizumab, camrelizumab
Jiangsu HengRui Medicine Co., Ltd.
Non-small Cell Lung Cancer
12/23
12/25
NCT06616532: PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer

Recruiting
3
404
RoW
PM8002, Paclitaxel, Topotecan
Biotheus Inc.
SCLC
01/27
12/28
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Recruiting
3
1016
Europe, Canada, Japan, US, RoW
LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed
Eli Lilly and Company, Loxo Oncology, Inc.
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
10/26
10/29
TQB3616-ALTN-II-01, NCT04924192: A Clinical Study of TQB3616 Capsules Combined With Anlotinib Hydrochloride Capsules or Standard Chemotherapy Second-line and Above in the Treatment of Advanced Lung Cancer

Recruiting
2
126
RoW
TQB3616 capsules, Anlotinib Hydrochloride capsules, Irinotecan Hydrochloride for Injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Lung Carcinoma
05/23
12/23
ACTIVE, NCT04882345: Almonertinib Treats Advanced NSCLC Patients With EGFR Mutations Who Are Safety Intolerant After Osimertinib Treatment

Not yet recruiting
2
40
NA
Almonertinib, HS-10296
Shanghai Chest Hospital, Jiangsu Hansoh Pharmaceutical Co., Ltd.
Lung Cancer, EGFR Gene Mutation
01/24
01/24
NCT05168566: Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer

Recruiting
2
99
US, RoW
Sutetinib Maleate Capsule, Sutetinib
Teligene US
Non-small Cell Lung Cancer
08/24
02/25
SKB264-II-04, NCT05816252: A Study of SKB264 for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

Recruiting
2
498
Europe, RoW
SKB264, MK-2870, Pembrolizumab, MK-3475, Carboplatin, Carboplatin for injection, Osimertinib, Osimertinib Mesylate
Klus Pharma Inc., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Non-small Cell Lung Cancer
12/25
10/26
NCT06500676: A Study of GFH375 in Patients with Advanced Solid Tumors with KRAS G12D Mutations

Recruiting
1/2
290
RoW
GFH375
Genfleet Therapeutics (Shanghai) Inc.
KRAS G12D Mutations, Advanced Solid Tumors
07/28
12/28
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies

Recruiting
1/2
1300
Canada, US, RoW
SKB264
Klus Pharma Inc.
Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer
08/25
07/26
TRIDENT-1, NCT03093116 / 2016-003616-13: A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Hourglass Jan 2025 - Jan 2025 : Approval in EU for adv ROS1+ve NSCLC, adv NTRK+ve solid tumors
Hourglass Jan 2023 - Dec 2023 : Data readout from P1/2 TRIDENT-1 trial for ROS1 NSCLC and NTRK+ solid tumors
Jan 2023 - Dec 2023: Approval in US for 2L NSCLC
Hourglass Jul 2023 - Dec 2023 : Approval for ROS1+ NSCLC
Checkmark Top line data across ROS1-positive TKI-naïve and TKI-pretreated NSCLC cohorts in TRIDENT-1 trial
More
Recruiting
1/2
500
Europe, Canada, Japan, US, RoW
Oral repotrectinib (TPX-0005), repotrectinib
Turning Point Therapeutics, Inc., Zai Lab (Shanghai) Co., Ltd.
Locally Advanced Solid Tumors, Metastatic Solid Tumors
02/28
02/28
SHR-A2009-I-101, NCT05114759: A Phase I Clinical Study of SHR-A2009 for Injection in Patients With Advanced Solid Tumors

Recruiting
1
132
Japan, RoW
SHR-A2009
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Advanced Solid Tumors
12/23
12/24
NCT06225804: A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK112 in Patients With Non-Small Cell Lung Cancer

Recruiting
1
164
US, RoW
ABSK112, EGFR Exon20 inhibitor
Abbisko Therapeutics Co, Ltd
Non-Small Cell Lung Cancer
03/27
03/28
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Townsend, Amanda
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
Lu, Shun
RATIONALE-304, NCT03663205: A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous Non-small Cell Lung Cancer

Checkmark Submitted for adv/met 2L NSCLC; in combination with carboplatin & either paclitaxel/ nab-paclitaxel for adv/met 1L sqNSCLC and; pemetrexed & platinum-containing chemotherapy for adv/met 1L non-sq NSCLC
Apr 2022 - Apr 2022: Submitted for adv/met 2L NSCLC; in combination with carboplatin & either paclitaxel/ nab-paclitaxel for adv/met 1L sqNSCLC and; pemetrexed & platinum-containing chemotherapy for adv/met 1L non-sq NSCLC
Checkmark Approved in China for 1L treatment of advanced NSCLC
Jun 2021 - Jun 2021: Approved in China for 1L treatment of advanced NSCLC
Checkmark From trial in combination with chemotherapy for 1L NSCLC at ESMO 2020
More
Completed
3
334
RoW
Tislelizumab, Tevimbra, BGB-A317, Cisplatin, Carboplatin, Pemetrexed
BeiGene
Non-Small Cell Lung Cancer
01/20
04/23
FGCL-4592-898, NCT05301517: A Study to Evaluate the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Participants Receiving Chemotherapy Treatment for Non-Myeloid Malignancies

Completed
3
159
RoW
SEPO®, Recombinant human erythropoietin-α [rHuEPO-α], Roxadustat, FG-4592
FibroGen
Chemotherapy Induced Anemia
04/23
04/23
ORIENT-31, NCT03802240: Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure

Hourglass Jan 2022 - Dec 2022 : Approval for 2L NSCLC
Checkmark Interim analysis results of P3 ORIENT-31 study in EGFR-mutated non-squamous NSCLC at ESMO 2022
Sep 2022 - Sep 2022: Interim analysis results of P3 ORIENT-31 study in EGFR-mutated non-squamous NSCLC at ESMO 2022
Checkmark Accepted sNDA in China for EGFR-mutated non-squamous NSCLC who progressed after EGFR-TKI therapy
Dec 2021 - Dec 2021: Accepted sNDA in China for EGFR-mutated non-squamous NSCLC who progressed after EGFR-TKI therapy
More
Completed
3
492
RoW
Sintilimab, IBI308, IBI305, Pemetrexed, Cisplatin, Placebo1, Placebo2
Innovent Biologics (Suzhou) Co. Ltd.
Non-Squamous Non-Small Cell Lung Cancer
07/21
06/23
ZKAB001-LEES-2020-07, NCT04878016: A Study of Carboplatin Plus Etoposide With or Without ZKAB001 (Anti-PD-L1 Antibody) in Patients With ES-SCLC

Completed
3
498
RoW
ZKAB001, Placebo, Carboplatin, Etoposide
Lee's Pharmaceutical Limited
Extensive-stage Small-cell Lung Cancer
10/23
10/23
LAURA, NCT03521154 / 2018-001061-16: A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer

Hourglass Jan 2022 - Dec 2023 : From LAURA trial for unresectable EGFRm stage III NSCLC
Hourglass Jan 2022 - Dec 2023 : Acceptance of regulatory submission in US (based on LAURA trial) for unresectable NSCLC
Active, not recruiting
3
216
Europe, Japan, US, RoW
Osimertinib 80mg/40mg, Placebo Osimertinib 80mg/40mg
AstraZeneca
Non Small Cell Lung Cancer (Stage III)
01/24
06/26
AENEAS2, NCT04923906: Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR Mutations

Active, not recruiting
3
624
RoW
Aumolertinib, HS-10296, Placebo Aumolertinib
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Non-small Cell Lung Cancer
06/24
01/26
NCT06300177: D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure

Recruiting
3
522
RoW
D-1553 Tablet, Docetaxel injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Non Small Cell Lung Cancer
10/26
12/27
NCT04923945: Savolitinib for Treating Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Patients

Recruiting
3
163
RoW
Savolitinib
Hutchison Medipharma Limited
Non-small Cell Lung Cancer Metastatic
07/24
12/24
SHR-A1811-310, NCT06430437: A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations

Not yet recruiting
3
300
RoW
SHR-A1811, Camrelizumab、Pemetrexed/ Paclitaxel、Carboplatin/ Cisplatin
Jiangsu HengRui Medicine Co., Ltd.
Non-Small Cell Lung Cancer With HER2- Mutations
02/26
04/27
SACHI, NCT05015608: Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification

Recruiting
3
250
RoW
Savolitinib + Osimertinib, Pemetrexed + Cisplatin /Carboplatin
Hutchison Medipharma Limited
Non-small Cell Lung Cancer
09/24
11/24
AK112-306, NCT05840016: AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer

Recruiting
3
396
RoW
AK112, Carboplatin, Paxlitaxel, Tislelizumab, Carboplatin, Paxlitaxel
Akeso
Advanced Squamous Non Small Cell Lung Cancer
12/24
12/25
AdvanTIG-302, NCT04746924 / 2020-004985-21: A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

Active, not recruiting
3
662
Europe, Japan, US, RoW
Tislelizumab, BGB-A317, Ociperlimab, BGB-A1217, Pembrolizumab, KEYTRUDA, Placebo
BeiGene
Non-small Cell Lung Cancer, NSCLC
10/26
02/27
SAFFRON, NCT05261399 / 2021-006374-24: Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment

Recruiting
3
324
Europe, Canada, Japan, US, RoW
Savolitinib, AZD6094, HMPL-504, volitinib, Osimertinib, AZD9291, Tagrisso, Pemetrexed, NAP, Cisplatin, Carboplatin
AstraZeneca, AstraZeneca AB
Carcinoma, Non-Small-Cell Lung
06/25
12/26
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Recruiting
3
1016
Europe, Canada, Japan, US, RoW
LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed
Eli Lilly and Company, Loxo Oncology, Inc.
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
10/26
10/29
NCT06041776: Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations

Recruiting
3
570
RoW
Befotertinib + Icotinib placebo, Icotinib + Befotertinib placebo
Betta Pharmaceuticals Co., Ltd.
Non-Small Cell Lung Cancer, EGFR Sensitive Mutation, Adjuvant Therapy
04/28
11/29
NCT04206072: D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLC

Active, not recruiting
2/3
362
RoW
D-0316 Capsule, Icotinib Hydrochloride Tablets, Conmana
Betta Pharmaceuticals Co., Ltd.
Non-Small Cell Lung Cancer, EGFR Gene Mutation
07/22
12/24
NCT04412564: A Study of TQ-B3101 Capsules in Subjects With Advanced Malignant Tumor

Recruiting
2
200
RoW
TQ-B3101
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Malignant Tumor
03/21
09/21
NCT03861156: D-0316 in Patients With EGFR Positive Non Small Cell Lung Cancer

Completed
2
290
RoW
D-0316
InventisBio Co., Ltd
Solid Tumor, NSCLC, EGFR T790M
08/21
05/23
NCT02897479: A Phase II Study of HMPL-504 in Lung Sarcomatoid Carcinoma and Other Non-small Cell Lung Cancer

Active, not recruiting
2
76
RoW
Savolitinib, hmpl-504
Hutchison Medipharma Limited
Lung Sarcomatoid Carcinoma
12/21
12/21
NCT05078931: A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients

Recruiting
2
35
RoW
Pembrolizumab, Keytruda, Lenvatinib, Lenvima
Shanghai Chest Hospital, Merck Sharp & Dohme Corp.
NSCLC
10/22
05/24
NCT04290325: HMPL-453 in Advanced Malignant Mesothelioma

Recruiting
2
27
RoW
HMPL-453
Hutchison Medipharma Limited
Advanced Malignant Mesothelioma
11/22
03/23
NCT06147570: A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

Recruiting
2
62
RoW
HS-10365 capsules
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Nonsmall Cell Lung Cancer
08/27
08/28
MRG002-008, NCT05141786: A Study of MRG002 in the Treatment of Patients With HER2-mutated Unresectable/Metastatic Non-small Cell Lung Cancer (NSCLC).

Not yet recruiting
2
100
RoW
MRG002
Shanghai Miracogen Inc.
Non-small- Cell Lung Cancer (NSCLC)
12/23
12/23
NCT06737081: SAL-0951 in the Treatment of Chemotherapy-induced Anemia in Patients With Non-myeloid Malignancies

Recruiting
2
60
RoW
SAL-0951 tablets 4mg, SAL-0951 tablets 4mg group, SAL-0951 tablets 5mg, SAL-0951 tablets 5mg group
Shenzhen Salubris Pharmaceuticals Co., Ltd.
Anemia
12/25
06/26
SOUND, NCT05374603: Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC

Active, not recruiting
2
47
RoW
Savolitinib, Durvalumab
AstraZeneca
Lung Cancer
08/25
08/25
NCT06668103: A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib

Recruiting
2
54
RoW
ABSK043 in combination with Firmonertinib
Abbisko Therapeutics Co, Ltd
Non-Small Cell Lung Cancer With EGFR Mutation
12/27
06/28
HLX26HLX10-NSCLC201, NCT05787613: A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC Patients

Recruiting
2
132
RoW
HLX26, Anti-LAG-3 monoclonal Antibody Injection, Serplulimab, HLX10, Chemotherapy drug, Placebo
Shanghai Henlius Biotech
NSCLC Stage IV
07/25
07/27
NCT06373406: A Study of MHB036C for Advanced Solid Tumor

Recruiting
1/2
200
RoW
MHB036C
Minghui Pharmaceutical (Hangzhou) Ltd
Advanced Solid Tumor
08/24
12/24
GLORY, NCT04270591: Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer

Recruiting
1/2
183
Japan, US, RoW
Glumetinib, SCC244
Haihe Biopharma Co., Ltd.
C-Met Exon 14 Mutation
10/23
12/23
SHR-A1811-II-203, NCT05482568: A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer

Recruiting
1/2
324
RoW
SHR-A1811 & Pyrotinib/SHR-A1811 & SHR-1316
Jiangsu HengRui Medicine Co., Ltd.
Advanced Non-small Cell Lung Cancer
11/23
12/24
NCT05383898: Study to Evaluate D-1553 in Subjects With Lung Cancer

Completed
1/2
225
RoW
D-1553
InventisBio Co., Ltd
NSCLC
11/23
05/24
NCT05492045: A Study to Evaluate D-1553 in Combination Therapy in Non-Small Cell Lung Cancer

Terminated
1/2
22
RoW
D-1553, Other
InventisBio Co., Ltd
NSCLC
06/24
06/24
NCT05207787: Phase Ⅰ/Ⅱ Study of the HS-10365 in Patients With Advanced Solid Tumors

Recruiting
1/2
306
RoW
HS-10365
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Solid Tumor
04/24
12/25
NCT06500676: A Study of GFH375 in Patients with Advanced Solid Tumors with KRAS G12D Mutations

Recruiting
1/2
290
RoW
GFH375
Genfleet Therapeutics (Shanghai) Inc.
KRAS G12D Mutations, Advanced Solid Tumors
07/28
12/28
NCT06283719: Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer

Recruiting
1/2
105
RoW
ZG006
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Small Cell Lung Cancer, Neuroendocrine Cancer
04/26
04/26
NCT06754930: A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC

Not yet recruiting
1/2
400
RoW
SHR-1826, SHR-1316, SHR-9839, SHR-8068, Ametinib mesylate, BP-102, Carboplatin
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Non-small Cell Lung Cancer (NSCLC)
12/27
12/27
NCT05552781: H002 in Patients With EGFR Mutation Locally Advanced or Metastatic NSCLC

Recruiting
1/2
76
RoW
H002 capsule, H002
RedCloud Bio, R&G Pharma Studies Co.,Ltd.
Non-small Cell Lung Cancer
02/25
02/25
NCT05641493: A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of HLX208+HLX10 in NSCLC With BRAF V600E Mutation

Recruiting
1/2
49
RoW
HLX208+HLX10
Shanghai Henlius Biotech
Non Small Cell Lung Cancer
03/25
02/26
NCT05951608: A Phase Ib/II Clinical Study of AK127 in Combination With AK112 in Patients With Advanced Solid Tumors

Not yet recruiting
1/2
216
NA
AK127 in combination with AK112
Akeso
Advanced Solid Tumors
07/25
07/26
NCT05731518: SC0245 and Irinotecan in Treating Patients With Relapsed Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

Recruiting
1/2
67
RoW
SC0245, SC0245 tablet, Irinotecan, Irinotecan hydrochloride injection
Biocity Biopharmaceutics Co., Ltd.
Small Cell Lung Cancer
09/25
02/26
DB-1310-O-1001, NCT05785741: A Study of DB-1310 in Advanced/Metastatic Solid Tumors

Recruiting
1/2
1000
US, RoW
DB-1310, Trastuzumab, Osimertinib
DualityBio Inc.
Advanced Solid Tumor
08/26
08/26
TRIDENT-1, NCT03093116 / 2016-003616-13: A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Hourglass Jan 2025 - Jan 2025 : Approval in EU for adv ROS1+ve NSCLC, adv NTRK+ve solid tumors
Hourglass Jan 2023 - Dec 2023 : Data readout from P1/2 TRIDENT-1 trial for ROS1 NSCLC and NTRK+ solid tumors
Jan 2023 - Dec 2023: Approval in US for 2L NSCLC
Hourglass Jul 2023 - Dec 2023 : Approval for ROS1+ NSCLC
Checkmark Top line data across ROS1-positive TKI-naïve and TKI-pretreated NSCLC cohorts in TRIDENT-1 trial
More
Recruiting
1/2
500
Europe, Canada, Japan, US, RoW
Oral repotrectinib (TPX-0005), repotrectinib
Turning Point Therapeutics, Inc., Zai Lab (Shanghai) Co., Ltd.
Locally Advanced Solid Tumors, Metastatic Solid Tumors
02/28
02/28
NCT03976856: Safety and Efficacy of Genolimzumab (GB226) in Combination With Fruquintinib

Recruiting
1
42
RoW
GB226, Geptanolimab, Fruquintinib, HMPL-013
Genor Biopharma Co., Ltd., Hutchison Medipharma Limited
Metastatic Non-small Cell Lung Cancer
12/21
12/22
NCT04671849: An Open Label, Multi-center, Phase I Clinical Study to Evaluate the Safety, Effectiveness and Pharmacokinetic Characteristics of SIM1803-1A in Patients With Locally Advanced/Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene Fusion Mutations.

Recruiting
1
243
RoW
SIM1803-1A
Jiangsu Simcere Pharmaceutical Co., Ltd.
Advanced or Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene Fusion
09/22
01/24
NCT04346914: Study of ZKAB001 Combined With Carboplatin and Etoposide in the Extensive Small Cell Lung Cancer

Recruiting
1
20
RoW
recombinant anti-PD-L1 monoclonal antibody injection combined with carboplatin and etoposide
Lee's Pharmaceutical Limited
Extensive Stage Small Cell Lung Cancer
10/22
10/22
NCT04866485: A Study to Evaluate Safety, Tolerability, PK/PD and Preliminary Efficacy of HBM4003 Combined With Anti-PD-1 Antibody

Not yet recruiting
1
66
NA
HBM4003 and pembrolizumab, HBM4003
Harbour BioMed (Guangzhou) Co. Ltd.
Solid Tumor
02/23
02/23
NCT05055232: A Phase I Study of XZP-3621 in Chinese Patients With ALK or ROS1 Rearrangement Non-small Cell Lung Cancer

Recruiting
1
120
RoW
XZP-3621
Xuanzhu Biopharmaceutical Co., Ltd.
ROS1 Rearrangement Non-small Cell Lung Cancer, ALK Rearrangement Non-small Cell Lung Cancer
03/23
09/23
NCT05393063: A Study to Evaluate the Efficacy and Safety of AK127 in Patients With Advanced Solid Tumors

Not yet recruiting
1
36
NA
AK127, Subjects will receive AK127 by intravenous administration
Akeso
Advanced Solid Tumors
06/23
06/24
NCT05315180: A Phase 1,Open-label Study of BPI-421286 in Subjects With Advanced Solid Tumors

Recruiting
1
80
RoW
BPI-421286
Betta Pharmaceuticals Co., Ltd.
Malignant Neoplasms, Metastatic Cancer
07/23
07/23
NCT05223595: A Study of Gentuximab in Combination With Almonertinib in EGFR Mutation-positive Metastatic NSCLC

Recruiting
1
42
RoW
Gentuximab, Almonertinib
GeneScience Pharmaceuticals Co., Ltd.
Metastatic Non-Small Cell Lung Cancer
09/23
01/24
NCT04843033: A Study to Investigate Safety and Tolerability of SH3809 Tablet in Patients With Advanced Solid Tumors

Recruiting
1
55
RoW
SH3809 tablet
Nanjing Sanhome Pharmaceutical, Co., Ltd.
Advanced Solid Tumor
10/23
12/23
NCT05430386: Study of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLC

Recruiting
1
174
RoW
HS-10241, Almonertinib
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Non Small Cell Lung Cancer
12/23
12/23
NCT06225804: A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK112 in Patients With Non-Small Cell Lung Cancer

Recruiting
1
164
US, RoW
ABSK112, EGFR Exon20 inhibitor
Abbisko Therapeutics Co, Ltd
Non-Small Cell Lung Cancer
03/27
03/28
AK112-103, NCT05116007: Anti-PD-1 and VEGF Bispecific Antibody AK112 in Combination With Chemotherapy in Patients With ES-SCLC

Completed
1
35
RoW
AK112, Etoposide, Carboplatin
Akeso
SCLC, Extensive Stage
12/23
12/23
NCT05653869: A Study of APS03118 in Advanced Solid Tumors Harboring RET Mutations or Fusions

Recruiting
1
35
RoW
APS03118, APS03118 administrated orally
Applied Pharmaceutical Science, Inc.
RET-altered Solid Tumors
04/24
04/25
NCT06328439: A Study to Evaluate ANS014004 in Subjects With Locally Advanced or Metastatic Solid Tumors

Recruiting
1
264
RoW
ANS014004
Avistone Biotechnology Co., Ltd., Shanghai Chest Hospital, Hunan Cancer Hospital, Henan Cancer Hospital, Zhejiang Cancer Hospital, Peking University Cancer Hospital & Institute
Locally Advanced or Metastatic Solid Tumors
12/27
01/28
CIBI363A103, NCT06468098: A Study of IBI363 in Subjects With Advanced Malignancies

Recruiting
1
556
RoW
IBI363 + chemotherapy, IBI363 + Investigator's Choice SOC
Innovent Biologics (Suzhou) Co. Ltd.
Advanced Malignancies
06/25
12/26
MIZAR-005, NCT06473961: A Phase Ⅰb Study on Autologous GC101 TIL Injection for the Treatment of NSCLC

Recruiting
1
20
RoW
Autologous Tumor Infiltrating Lymphocytes, GC101 TIL injection
Shanghai Juncell Therapeutics
Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer
01/26
07/27
NCT05244551: A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors

Recruiting
1
85
US, RoW
ABSK061
Abbisko Therapeutics Co, Ltd
Solid Tumor
04/25
04/25
NCT05717348: A Study of ES014 in Patients With Locally Advanced or Metastatic Solid Tumours

Recruiting
1
120
RoW
ES014
Elpiscience (Suzhou) Biopharma, Ltd.
Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor
06/25
09/25
NCT05911464: A Phase I Study of HS-10386 in Participants With Advanced Solid Tumors

Recruiting
1
248
RoW
HS-10386
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Advanced Solid Tumor
10/25
10/27
NCT05914545: A Study of FZ-AD004 in Patients with Advanced Solid Tumors

Recruiting
1
121
RoW
FZ-AD004, FZ-AD004-Antibody-drug Conjugate
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Advanced and Metastatic Solid Tumor
12/25
12/25
NCT06015568: Study of MCLA-129 Combined With Befotertinib in the Treatment of Advanced Non-small Cell Lung Cancer With EGFR Sensitive Mutation

Not yet recruiting
1
172
RoW
MCLA-129: 1500mg or 2000mg IV Q2W, Befotertinib: 75 mg or 100 mg Po QD
Betta Pharmaceuticals Co., Ltd.
Non-Small Cell Lung Cancer、EGFR Sensitive Mutation
11/28
07/29
NCT04566432: Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated NSCLC Patients

Recruiting
N/A
250
RoW
Observation
Geneplus-Beijing Co. Ltd., Shanghai Chest Hospital
Lung Neoplasms, Lung Cancer, Nonsmall Cell, Adenocarcinoma of Lung, Squamous Cell Lung Cancer
12/24
06/25
NCT05965557: Exploration of Predictive Markers of Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer

Recruiting
N/A
100
RoW
Geneplus-Beijing Co. Ltd.
Lung Cancer
12/25
12/25
MEANING-20, NCT05863819: A Real World Study of Mobocertinib in Adults With Lung Cancer in China (MEANING)

Withdrawn
N/A
120
RoW
No Intervention
Takeda
Non-small Cell Lung Cancer (NSCLC)
12/26
02/27
Yao, Wenxiu
OFFER, NCT04536558: Olanzapine Plus Fosaprepitant Standard Antiemetic Therapy in the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients Receiving High Emetic Risk Multi-day Chemotherapy: a Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study

Not yet recruiting
3
352
RoW
olanzapine plus fosaprepitant-based triple regimen, placebo plus fosaprepitant-based triple regimen
Sun Yat-sen University, Jiangsu Hansoh Pharmaceutical Co., Ltd.
Solid Tumor Patients Receiving High Emetic Risk Multi-day Chemotherapy
02/21
03/21
PYRAMID-1, NCT04447118 / 2020-000951-11: Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy

Active, not recruiting
3
151
Europe, US, RoW
Pyrotinib, Irene, Docetaxel, Docetaxel injection
Jiangsu HengRui Medicine Co., Ltd.
Non-squamous NSCLC, HER2 Exon 20 Mutation
06/23
10/23
NCT05042375: A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer

Recruiting
3
450
RoW
camrelizumab + famitinib, pembrolizumab, camrelizumab
Jiangsu HengRui Medicine Co., Ltd.
Non-small Cell Lung Cancer
12/23
12/25
NCT06616532: PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer

Recruiting
3
404
RoW
PM8002, Paclitaxel, Topotecan
Biotheus Inc.
SCLC
01/27
12/28
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Recruiting
3
1016
Europe, Canada, Japan, US, RoW
LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed
Eli Lilly and Company, Loxo Oncology, Inc.
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
10/26
10/29
TQB3616-ALTN-II-01, NCT04924192: A Clinical Study of TQB3616 Capsules Combined With Anlotinib Hydrochloride Capsules or Standard Chemotherapy Second-line and Above in the Treatment of Advanced Lung Cancer

Recruiting
2
126
RoW
TQB3616 capsules, Anlotinib Hydrochloride capsules, Irinotecan Hydrochloride for Injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Lung Carcinoma
05/23
12/23
ACTIVE, NCT04882345: Almonertinib Treats Advanced NSCLC Patients With EGFR Mutations Who Are Safety Intolerant After Osimertinib Treatment

Not yet recruiting
2
40
NA
Almonertinib, HS-10296
Shanghai Chest Hospital, Jiangsu Hansoh Pharmaceutical Co., Ltd.
Lung Cancer, EGFR Gene Mutation
01/24
01/24
NCT05168566: Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer

Recruiting
2
99
US, RoW
Sutetinib Maleate Capsule, Sutetinib
Teligene US
Non-small Cell Lung Cancer
08/24
02/25
SKB264-II-04, NCT05816252: A Study of SKB264 for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

Recruiting
2
498
Europe, RoW
SKB264, MK-2870, Pembrolizumab, MK-3475, Carboplatin, Carboplatin for injection, Osimertinib, Osimertinib Mesylate
Klus Pharma Inc., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Non-small Cell Lung Cancer
12/25
10/26
NCT06500676: A Study of GFH375 in Patients with Advanced Solid Tumors with KRAS G12D Mutations

Recruiting
1/2
290
RoW
GFH375
Genfleet Therapeutics (Shanghai) Inc.
KRAS G12D Mutations, Advanced Solid Tumors
07/28
12/28
KL264-01, NCT04152499: Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies

Recruiting
1/2
1300
Canada, US, RoW
SKB264
Klus Pharma Inc.
Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer
08/25
07/26
TRIDENT-1, NCT03093116 / 2016-003616-13: A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Hourglass Jan 2025 - Jan 2025 : Approval in EU for adv ROS1+ve NSCLC, adv NTRK+ve solid tumors
Hourglass Jan 2023 - Dec 2023 : Data readout from P1/2 TRIDENT-1 trial for ROS1 NSCLC and NTRK+ solid tumors
Jan 2023 - Dec 2023: Approval in US for 2L NSCLC
Hourglass Jul 2023 - Dec 2023 : Approval for ROS1+ NSCLC
Checkmark Top line data across ROS1-positive TKI-naïve and TKI-pretreated NSCLC cohorts in TRIDENT-1 trial
More
Recruiting
1/2
500
Europe, Canada, Japan, US, RoW
Oral repotrectinib (TPX-0005), repotrectinib
Turning Point Therapeutics, Inc., Zai Lab (Shanghai) Co., Ltd.
Locally Advanced Solid Tumors, Metastatic Solid Tumors
02/28
02/28
SHR-A2009-I-101, NCT05114759: A Phase I Clinical Study of SHR-A2009 for Injection in Patients With Advanced Solid Tumors

Recruiting
1
132
Japan, RoW
SHR-A2009
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Advanced Solid Tumors
12/23
12/24
NCT06225804: A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK112 in Patients With Non-Small Cell Lung Cancer

Recruiting
1
164
US, RoW
ABSK112, EGFR Exon20 inhibitor
Abbisko Therapeutics Co, Ltd
Non-Small Cell Lung Cancer
03/27
03/28

Download Options